Compare OLLI & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLLI | RYTM |
|---|---|---|
| Founded | 1982 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 6.4B |
| IPO Year | 2015 | 2017 |
| Metric | OLLI | RYTM |
|---|---|---|
| Price | $89.69 | $76.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 14 |
| Target Price | ★ $140.38 | $131.14 |
| AVG Volume (30 Days) | ★ 1.4M | 914.5K |
| Earning Date | 03-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.43 | ★ 28.34 |
| EPS | ★ 3.89 | N/A |
| Revenue | ★ $2,649,198,000.00 | N/A |
| Revenue This Year | $15.62 | $55.17 |
| Revenue Next Year | $11.30 | $95.98 |
| P/E Ratio | $23.26 | ★ N/A |
| Revenue Growth | ★ 16.62 | N/A |
| 52 Week Low | $90.37 | $45.91 |
| 52 Week High | $141.74 | $122.20 |
| Indicator | OLLI | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 26.71 | 31.50 |
| Support Level | N/A | $60.71 |
| Resistance Level | $119.66 | $98.37 |
| Average True Range (ATR) | 4.13 | 5.71 |
| MACD | -1.46 | -0.74 |
| Stochastic Oscillator | 4.58 | 0.08 |
Ollie's Bargain Outlet Holdings Inc is a retailer of closeout merchandise and excess inventory. The company sells name brand household related items that consumers use in their everyday lives at prices that are heavily discounted below traditional retailers. It offers customers a broad selection of brand name products, including housewares, bed and bath, food, floor coverings, health and beauty aids, books and stationery, toys, and electronics. It operates stores across the Eastern half of the United States. Its differentiated go-to-market plan is characterized by a fun and engaging treasure hunt shopping experience, compelling customer value proposition, and witty, humorous in-store signage and advertising campaigns.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.